David Meininger

David Meininger

UNVERIFIED PROFILE

Are you David Meininger?   Register this Author

Register author
David Meininger

David Meininger

Publications by authors named "David Meininger"

Are you David Meininger?   Register this Author

13Publications

249Reads

-Profile Views

Molecular basis of sphingosine kinase 1 substrate recognition and catalysis.

Structure 2013 May 18;21(5):798-809. Epub 2013 Apr 18.

Department of Molecular Structure and Characterization, Amgen, Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.str.2013.02.025DOI Listing
May 2013

In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b(5) and methylene blue.

Biochemistry 2010 Mar;49(12):2647-56

Biochemistry and Biophysics Group, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119-3105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi100022cDOI Listing
March 2010

Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

Bioorg Med Chem 2008 Oct 29;16(19):8922-31. Epub 2008 Aug 29.

Department of Metabolic Disorders, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2008.08.065DOI Listing
October 2008

The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33.

Cytokine 2008 Jun 2;42(3):358-64. Epub 2008 May 2.

Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau-Séjour, 1211 Geneva 14, Switzerland.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S104346660800091
Publisher Site
http://dx.doi.org/10.1016/j.cyto.2008.03.008DOI Listing
June 2008

NMR-based structural characterization of large protein-ligand interactions.

J Biomol NMR 2002 Feb;22(2):165-73

Triad Therapeutics, Inc., San Diego 92121, USA.

View Article

Download full-text PDF

Source
February 2002